Stock Traders Purchase High Volume of Put Options on Maravai LifeSciences (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) was the target of some unusual options trading on Wednesday. Investors bought 1,002 put options on the stock. This represents an increase of 1,791% compared to the average volume of 53 put options.

Insider Activity

In related news, General Counsel Kurt Oreshack sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $5.03, for a total value of $125,750.00. Following the transaction, the general counsel now directly owns 167,618 shares of the company’s stock, valued at approximately $843,118.54. The trade was a 12.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.63% of the company’s stock.

Institutional Trading of Maravai LifeSciences

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. boosted its stake in Maravai LifeSciences by 1,172.4% during the third quarter. JPMorgan Chase & Co. now owns 4,050,245 shares of the company’s stock worth $33,658,000 after buying an additional 3,731,924 shares during the period. Barclays PLC boosted its stake in shares of Maravai LifeSciences by 349.2% during the 3rd quarter. Barclays PLC now owns 184,189 shares of the company’s stock worth $1,531,000 after purchasing an additional 143,184 shares during the period. Systematic Financial Management LP grew its holdings in Maravai LifeSciences by 14.7% during the 3rd quarter. Systematic Financial Management LP now owns 1,612,161 shares of the company’s stock valued at $13,397,000 after purchasing an additional 206,499 shares during the last quarter. Empowered Funds LLC purchased a new stake in Maravai LifeSciences in the 4th quarter worth about $155,000. Finally, Bleakley Financial Group LLC lifted its stake in Maravai LifeSciences by 30.1% in the fourth quarter. Bleakley Financial Group LLC now owns 41,691 shares of the company’s stock worth $227,000 after purchasing an additional 9,657 shares during the last quarter. Hedge funds and other institutional investors own 50.25% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on MRVI. Baird R W downgraded shares of Maravai LifeSciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 26th. Morgan Stanley dropped their price objective on shares of Maravai LifeSciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a report on Tuesday, March 25th. UBS Group cut their price objective on Maravai LifeSciences from $8.00 to $2.50 and set a “neutral” rating for the company in a research report on Friday, March 21st. Robert W. Baird cut Maravai LifeSciences from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $9.00 to $3.00 in a report on Wednesday, February 26th. Finally, The Goldman Sachs Group lowered Maravai LifeSciences from a “neutral” rating to a “sell” rating and dropped their price target for the company from $7.00 to $4.25 in a research note on Thursday, December 5th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $7.31.

Maravai LifeSciences Trading Down 5.0 %

Shares of NASDAQ MRVI opened at $2.10 on Friday. The stock has a market capitalization of $534.11 million, a P/E ratio of -1.28 and a beta of -0.08. Maravai LifeSciences has a 1-year low of $2.05 and a 1-year high of $11.56. The business’s 50 day moving average is $3.48 and its two-hundred day moving average is $5.43. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.